Vol. 8, Issue 4 (2019)
Study on quality of life of type 2 diabetes mellitus patients managed with oral hypoglycemic agents vs both insulin and oral hypoglycemic agents in a tertiary care teaching hospital
S Monika, N Lakshmi Bhavani, G Suresh, Dr. PK Manna and Dr. S Balasubramaniyan
Diabetes mellitus is a chronic metabolic disorder resulting from the deficiency of insulin secretion or may be excessive insulin secretion. It is one of the major health problems among the worldwide and leads to an increase in the cause of morbidity and mortality rate. As per World Health Organization (WHO), around 31.7 million individuals in India were affected by diabetes during the year 2000 which may further rise to 79.4 million by the year 2030. The Indian Council of Medical Research India Diabetes study (ICMR-INDIAB study) showed that India had 62.4 million people with diabetes in 2011. The study findings showed that female patients were more affected in the age group of 41 to 50 years with 6-10 years duration of disease. The patients under both the regimens had co-morbidities associated with the disease. Metformin is the most commonly prescribed oral hypoglycaemic drug in the monotherapy (Regimen A) whereas in the combination therapy (Regimen B), Metformin + Glimepiride + Insulin was commonly prescribed. Among the Insulin prescribed in combined therapy, Human Insulin was prescribed more. As per the QOL studies based on the WHOQOL-BREF scale, the patients under Regimen A had poor QOL in physical health domain than the Psychological, Social and Environmental domains. The patients under Regimen B had good QOL in all the four domains. The study finding concludes that there was no significant difference in QOL in patients receiving Regimen A and Regimen B.
How to cite this article:
S Monika, N Lakshmi Bhavani, G Suresh, Dr. PK Manna, Dr. S Balasubramaniyan. Study on quality of life of type 2 diabetes mellitus patients managed with oral hypoglycemic agents vs both insulin and oral hypoglycemic agents in a tertiary care teaching hospital. Pharma Innovation 2019;8(4):471-474.